JADE101 for IgA Nephropathy Kidney Disease
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether JADE101, a new medicine, can help slow kidney damage in people with IgA nephropathy (a type of kidney disease caused by immune system problems). You'll take it alongside your current blood pressure medications for about 48 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Between 18 and 60 years old
- Kidney function test (eGFR) score of at least 30
- Confirmed IgA nephropathy diagnosis from a kidney biopsy
- Currently taking an ACE inhibitor or ARB blood pressure medication at a stable dose for at least 12 weeks
- Protein level in urine (UPCR) of at least 0.75 g/g
- Able to attend regular visits and follow study instructions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called CM313 in people with IgA nephropathy, a kidney disease. It may help reduce protein in the urine, which is a sign of kidney damage.
This study tests whether a new drug called BHV-1400 can slow down or help IgA nephropathy, a condition where the immune system damages the kidneys. You'll be monitored to see if the drug is safe and effective for you.
This trial tests an experimental medicine called NM8074 for people with IgA nephropathy, a type of kidney disease. It aims to see if NM8074 can help protect your kidneys and reduce damage.
This trial enrolls teens and adults with biopsy-proven IgA nephropathy to help doctors learn whether a specific care approach works better for high-quality treatment. It is meant for people whose IgA kidney disease is the primary form (not caused by another illness).
This trial tests whether hydroxychloroquine can help slow kidney damage in people with IgA nephropathy. You may qualify if you have this kidney disease, are already on two standard medicines (RAAS inhibitors and SGLT2 inhibitors), and have ongoing protein in your urine.
This trial tests a new drug, HS-10390, to see if it can help people with IgA nephropathy. You may qualify if you have the condition, are on stable blood pressure medication, and meet certain kidney function and lab criteria.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.